Type 2 Diabetes is one of the most commonly tested clinical areas in the PSA. It allows examiners to assess prescribing skills, medication review, adverse drug reactions, monitoring requirements, renal dose adjustments and patient safety within a single clinical scenario.
Many students prepare for answering questions on Type 2 Diabetes incorrectly. The strongest candidates do not simply memorise treatment pathways. They learn to identify the specific clue(s) the examiner has deliberately placed within the question and use that clue(s) to justify the safest prescribing decision using the BNF and their experience.
Following the February 2026 update to 'NG28: Type 2 Diabetes in Adults', there is now greater emphasis on cardiovascular protection, renal protection, obesity, frailty and individualised medicine selection, making Type 2 Diabetes an increasingly important PSA topic.
In this guide, we explore the prescribing decisions most likely to be tested in the PSA, explains how examiners think, and highlight the diabetes prescribing traps that catch candidates every year.
Type 2 Diabetes allows examiners to test multiple prescribing competencies simultaneously:
Drug selection
Prescription writing
Medication review
Monitoring requirements
Contraindications
Medicine optimisation
Adverse effects
Renal dose adjustment
Patient safety
Polypharmacy
This is precisely why diabetes repeatedly appears across prescribing, medicines management and prescription review stations. A PSA diabetes question is rarely testing whether you know a guideline. More often, it is assessing whether you can identify a safety issue and use the BNF appropriately.
In February 2026, NICE updated recommendations for:
Metformin
SGLT2 inhibitors
GLP-1 receptor agonists
DPP-4 inhibitors
Sulfonylureas
Pioglitazone
Insulin treatment pathways
The revised guideline places greater emphasis on comorbidity-driven prescribing decisions rather than focusing solely on HbA1c.
Modified-Release Metformin is Now Preferred
For many newly diagnosed patients, modified-release metformin is now recommended in preference to standard-release metformin.
SGLT2 Inhibitors Have Moved to the Front of the Pathway
Many patients should now receive:
Metformin MR + SGLT2 inhibitor
as initial pharmacological treatment because of proven cardiovascular and renal benefits.
Cardiovascular and Renal Protection Matter More Than Ever
Treatment decisions increasingly depend upon:
Atherosclerotic cardiovascular disease (ASCVD)
Heart failure
Chronic kidney disease (CKD)
Obesity
Frailty
The King is Down - Reverse Engineering the PSA: Type 2 Diabetes
The Examiner's Thought Process
Examiners rarely ask:
"Which diabetes guideline is correct?"
Instead they ask:
Which treatment is safest?
Which medicine should be started?
Which medicine should be withheld?
Which medicine is causing harm?
What monitoring is required?
Understanding this distinction is often the difference between an average score and an excellent one. When reviewing a diabetes scenario, ask yourself: "Why has the examiner included this piece of information?" The answer is usually the key to the question.
What Students Learn
Metformin is first-line treatment.
What Examiners Actually Test
The examiner is usually interested in:
Gastrointestinal side effects
Renal function
Tolerability
Appropriate medicine selection
A typical question may describe:
Newly diagnosed diabetes
Gastrointestinal intolerance
Poor adherence
Reduced renal function
The best answer may be switching to modified-release metformin rather than unnecessarily escalating treatment.
PSA Question Insight
Whenever metformin appears, immediately look for:
eGFR
Nausea
Diarrhoea
Medicine adherence
Recent illness
These details are often the true focus of the question.
Examples
Dapagliflozin
Empagliflozin
Students often recognise SGLT2 inhibitors as glucose-lowering drugs.
Examiners increasingly view them as medicines that:
Reduce cardiovascular risk
Reduce heart failure hospitalisation
Slow progression of CKD
Provide significant cardio-renal protection
These benefits have driven their expanded role within the updated pathway.
PSA Trap 1: Sick Day Rules
A patient develops:
Vomiting
Diarrhoea
Sepsis
Dehydration
The candidate is then asked to review medication. The examiner expects recognition that SGLT2 inhibitors may need to be temporarily withheld during acute illness.
Reverse Engineering Tip
Whenever you see:
✅ Acute illness
✅ Dehydration
✅ AKI risk
Immediately review diabetes medications.
PSA Trap 2: Euglycaemic DKA
This is a classic modern prescribing question. The patient may have:
Ketones
Acidosis
Abdominal pain
Vomiting
Yet glucose is not markedly elevated.
Reverse Engineering Tip
Many students incorrectly exclude diabetic ketoacidosis. The examiner wants you to remember that SGLT2 inhibitors may be associated with ketoacidosis despite relatively normal blood glucose concentrations.
Examples
Gliclazide
Glimepiride
Students often focus on glucose control. Examiners focus on hypoglycaemia.
Typical PSA scenario:
Elderly patient
Reduced oral intake
Missed meals
Confusion
Falls
Sweating
Question: Which medicine is most likely contributing? The answer is frequently: Gliclazide.
Reverse Engineering Tip
Whenever sulfonylureas appear in a scenario involving confusion or reduced food intake, hypoglycaemia should immediately enter your differential diagnosis.
Examples
Semaglutide
Liraglutide
The updated pathway places increased importance on GLP-1 receptor agonists in selected patient groups.
What the Examiner Really Wants
The question is rarely: What is semaglutide? It is more commonly: Why would semaglutide be an appropriate choice?
Look for:
Obesity
Cardiovascular disease
Poor glycaemic control
High future cardiovascular risk
These are often the clues driving medicine selection.
1. Renal Function
Always check:
eGFR
Urea and electrolytes
AKI history
If renal function is provided, it is almost always relevant.
2. Hypoglycaemia
Look for:
Confusion
Dizziness
Falls
Reduced consciousness
Sweating
Particularly when:
Insulin
Gliclazide
Sulfonylureas
appear in the medication history.
3. Sick Day Rules
Expect scenarios involving:
Acute illness
Gastroenteritis
Sepsis
Dehydration
These frequently test safe medicine withholding decisions.
4. Insulin Safety
Never underestimate insulin questions. Common themes include:
Omitted insulin
Incorrect doses
Prescribing errors
Incomplete prescriptions
These are classic patient-safety domains.
5. Cardiovascular Protection
Modern diabetes prescribing is no longer glucose-centric. Candidates should immediately consider:
ASCVD
Heart failure
CKD
Tier 1: Very High Yield
✅ Metformin MR prescribing
✅ SGLT2 inhibitor initiation
✅ Sick day rules
✅ CKD prescribing
✅ AKI and diabetes medicines
✅ Gliclazide-induced hypoglycaemia
✅ Insulin safety
✅ Medication review stations
✅ Cardiovascular-risk prescribing decisions
Tier 2: Increasing Importance
✅ Semaglutide
✅ GLP-1 receptor agonists
✅ Obesity-driven prescribing decisions
✅ Tirzepatide awareness
✅ Heart failure pathways
✅ CKD treatment pathways
✅ Combination therapy selection
The updated diabetes guidance increasingly emphasises comorbidity-driven treatment choices and cardio-renal protection.
Is Type 2 Diabetes commonly tested in the PSA?
Yes. Type 2 Diabetes is one of the highest-yield topics because it allows examiners to test prescribing, medication review, monitoring, adverse effects and patient safety within a single clinical scenario.
Which diabetes medicines should I know best for the PSA?
Focus on:
Metformin MR
SGLT2 inhibitors
Gliclazide
GLP-1 receptor agonists
Insulin
These medicines commonly appear in prescribing and medicines management questions.
Are SGLT2 inhibitors important for the PSA?
Absolutely. They provide a rich source of examination questions involving cardiovascular protection, CKD, sick day rules and ketoacidosis recognition.
What is the biggest mistake students make?
Many focus exclusively on HbA1c. The strongest candidates instead assess:
Renal function
Cardiovascular disease
Heart failure
Acute illness
Hypoglycaemia risk
Current medicines
Students often ask:
"What guideline should I memorise?"
A better question is:
"What clue in the question has the examiner deliberately included?"
In diabetes questions, the clue is usually:
eGFR
Current medication
BMI
Weight change
Acute illness
Cardiovascular disease
Heart failure
Hypoglycaemia symptoms
The BNF contains the answer. The PSA tests whether you can find it, interpret it and prescribe safely.
Type 2 Diabetes in 2026 is no longer simply about lowering HbA1c. Modern PSA questions increasingly reflect real-world prescribing decisions focused on:
Cardiovascular protection
Renal protection
Individualised treatment
Safe prescribing
Patient safety
Candidates who learn to reverse engineer the examiner's thinking consistently outperform those who rely on memorisation alone.
Remember:
The clue is usually hidden in the scenario.
The justification is usually in the BNF.
The skill is knowing how to connect the two.
Think Type 1 Diabetes is just about insulin?
Think again....
The next article in the series explores:
DKA recognition
Basal-bolus insulin regimens
Variable-rate insulin infusions
Hypoglycaemia treatment
Ketone monitoring
Insulin omission errors
The hidden clues PSA examiners use to test patient safety.
PSA Tutor UK - Learn how personalised PSA tutoring can help reduce stress and improve confidence.
PSA Success Centre - Explore free PSA guidance, revision tips and learning resources.
How to Pass the PSA First Time - Practical strategies for approaching the exam effectively.
Top 10 PSA Mistakes Students Make - Avoid common errors that can cost valuable marks.
PSA Calculations Made Easy - Build confidence in one of the most challenging PSA domains.
PSA High-Risk Medicines - Those drugs that often surface in the PSA due to their potentially dangerous nature.
Why Some Medical Students Choose a PSA Tutor - The benefits of having your own dedicated PSA tutor.
PSA Calculations Made Easy - Strategies to complete PSA calculation questions in a timely and effective way.